PubRank
Search
About
Kiyoko Kuwata
Author PubWeight™ 12.13
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
Clin Cancer Res
2012
1.71
2
MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
J Thorac Oncol
2011
1.29
3
Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
Mol Cancer Ther
2010
1.21
4
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Cancer Sci
2009
1.18
5
Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
Mol Cancer Ther
2012
1.12
6
MET amplification as a potential therapeutic target in gastric cancer.
Oncotarget
2013
1.09
7
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
Mol Cancer Ther
2010
1.07
8
Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
Cancer Res
2010
1.05
9
Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
Mol Cancer Ther
2011
0.98
10
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Mol Cancer Ther
2010
0.94
11
Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma.
Cancer Med
2013
0.81